Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Shutterstock
two in one

Pfizer-BioNTech to test combined Covid and flu vaccine

Pfizer and its German partner BioNTech developed one of the most widely used vaccines to combat Covid-19.

PFIZER-BIONTECH has said they will test a combined coronavirus and influenza vaccine, which could potentially pave the way for better inoculation uptake for both illnesses.

The companies said in a statement the mRNA-based combination vaccine candidate is set to progress to a phase one trial in the United States with 180 volunteers.

The inoculation “could simplify immunisation practices against these two respiratory pathogens, potentially leading to better vaccine uptake for both diseases,” said Annaliesa Anderson, head of vaccine research and development at US drugmaker Pfizer.

“Even with existing seasonal influenza vaccines, the burden of this virus is severe across the world, causing thousands of deaths and hospitalisations every year.”

Pfizer and its German partner BioNTech developed one of the most widely used vaccines to combat Covid-19.

Rival vaccine makers Moderna and Novavax have also been testing combined inoculations against Covid and flu.

© AFP 2022 

Your Voice
Readers Comments
23
This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
Leave a Comment
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.

    Leave a commentcancel